Biotech Firms Form New Industry Group

- The Midsized Biotech Alliance of America (MBAA) was formed by companies including Alkermes, BioMarin, Incyte, and Alnylam to advocate against "one-size-fits-all" drug pricing policies. Mid-sized firms are particularly concerned that pricing schemes negotiated by larger pharmaceutical companies will not work for them, as they often have fewer products and may have international licensing agreements that complicate U.S. pricing. - A separate group, the American Alliance for Biomanufacturing (AAB), was recently launched to accelerate U.S. leadership in the sector. Its mission includes streamlining regulations across the EPA, FDA, and USDA to create biotech-specific regulatory pathways, which could directly impact the complexity and cost of GMP manufacturing for viral vectors. - The formation of these groups is happening as legislation like the BIOSECURE Act gains momentum, which aims to prohibit federal funding for companies using equipment or services from "biotechnology companies of concern," including major China-based CDMOs. This is forcing U.S. biotech and their CDMO partners to re-evaluate supply chain resilience and prioritize domestic manufacturing capabilities. - For cell and gene therapy manufacturing, a key industry challenge driving policy discussions is the difficulty in scaling processes from clinical to commercial production. The complexity of custom-made treatments, like CAR-T therapies, requires advanced quality controls and sophisticated, often manual, manufacturing processes that differ significantly from traditional bulk drug production. - Automation and data integration are central to overcoming manufacturing bottlenecks in cell and gene therapy, but they also introduce regulatory challenges. Industry advocates are pushing for clearer FDA guidance on validating AI-enabled quality systems and ensuring the traceability of AI-supported clinical documentation, which will be critical for implementing digital twins and electronic batch records in a GMP environment. - Unpredictable funding cycles, which have seen a reduction in early-stage investment and a volatile IPO market, are a major driver for these new policy-focused alliances. Financial pressures force biotechs to seek a more predictable and favorable regulatory environment to de-risk development and attract investment for scaling up manufacturing operations. - The policy priorities of these new biotech groups often diverge from those of large pharmaceutical companies, represented by PhRMA. While both may lobby on drug pricing, biotech firms have a stronger focus on protecting innovation for novel platforms like gene therapies, which have different development and manufacturing economics than small-molecule drugs. - A core objective for the AAB is to bolster domestic supply chains for critical biological materials and manufacturing equipment. This aligns with national security interests and directly supports the infrastructure needed by CDMOs to avoid disruptions and ensure the timely production of therapies for U.S. patients.